Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study published ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...

Residual cancer can remain undetected despite clear scans, potentially leading to worse outcomes and higher risks of ...

The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

"Residual cancer is identified on histology in 40% of lung, 57–69% of renal cell, 7.7–47.6% of prostate and 0–86.7% of hepatocellular carcinoma." ...

Radiotherapy, especially a form known as stereotactic ablative radiotherapy (SABR), is widely used to treat cancers in the ...